Karyopharm Therapeutics Sees FY23 Revenue $145M-$160M Vs $150.34M Est.
Portfolio Pulse from Happy Mohamed
Karyopharm Therapeutics has provided its financial outlook for FY23, expecting total revenue to be between $145M-$160M, which includes U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. The company also expects non-GAAP R&D and SG&A expenses to be in the range of $240M-$255M, due to cost savings from further optimization of infrastructure and cost structure and workforce reduction of approximately 20%.
August 04, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karyopharm Therapeutics' FY23 revenue guidance is slightly below the estimated $150.34M. However, the company expects cost savings from infrastructure optimization and workforce reduction, which could offset the lower revenue.
Karyopharm's FY23 revenue guidance is slightly below the estimated $150.34M, which could negatively impact the stock. However, the company's plans for cost savings through infrastructure optimization and workforce reduction could offset this potential negative impact. Therefore, the short-term impact on the stock is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100